Biotech Co. To Face Amended Investor Suit Over COVID Test

By Sydney Price · May 1, 2023, 6:25 PM EDT

A California federal judge has declined to dismiss an amended investor complaint against a biotech company over issues with its COVID-19 test rollout, holding the revised suit plausibly alleges the defendants...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

IN RE Talis Biomedical Securities Litigation

Case Number

Court

California Northern

Nature of Suit

Securities/Commodities

Date Filed

January 07, 2022

Recent Articles By Sydney

November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 29, 2024
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 18, 2024
Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division